Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NovoCure Ltd

Get SEC filing alerts via email and in your feed for NovoCure Ltd

NVCR

NovoCure Ltd

About NovoCure Ltd

NovoCure Limited is a global oncology company specializing in Tumor Treating Fields (TTFields) technology, which uses electric fields to disrupt cancer cell division. Its core products, Optune Gio and Optune Lua, are medical devices approved for treating glioblastoma, non-small cell lung cancer, and mesothelioma. The company markets its therapies worldwide, emphasizing clinical research, regulatory compliance, and innovative device development to extend survival and improve quality of life for cancer patients.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from NovoCure Ltd

1
1
NovoCure Ltd NovoCure Reports 12% Revenue Growth to $174.1 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
NovoCure Ltd NovoCure Reports $655.4M Revenue and $136.2M Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
NovoCure Ltd NovoCure Reports 8% Revenue Growth to $167.2 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
NovoCure Ltd NovoCure Reports 6% Revenue Growth to $158.8 Million in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
NovoCure Ltd NovoCure Reports 19% Revenue Growth to $605.2 Million Despite Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
NovoCure Ltd NovoCure Reports 22% Revenue Growth, Improved Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments